Working together to combat malaria.
"...information at the molecular level is vital to gain insights
into the pathogenesis of malaria, and potentially offers
the opportunity to develop better drugs."
~ Subra Suresh
SAMI Board member profileOPPEL B.W. GREEFF
BIOSKETCH : OPPEL B.W. GREEFF Prof Greeff holds a Batchelors degree in Medicine and Surgery MBChB (Pret); Post graduate qualifications in Primary Health Care, FCFP (SA); MPharmMed (Pret); Pharmaceutical Medicine FFPM (Royal Colleges of Physicians (UK)) and a MD (Psychiatry) (KZN). From 1973 until 1977, Prof Greeff worked as a General Practitioner, was employed as Medical Advisor for Wellcome Southern Africa in 1978 and Medical Director with Roussel Laboratories from 1981 to 1990. During this period he was intimately involved in the commercialisation activities of both companies. In 1990 he founded Clindepharm International, the first Contract Research Organisation in South Africa, which he sold to Quintiles Transnational Corporation in August 1997 and continued his employment at Quintiles. In 2002 he was appointed CEO of Early Development & Laboratory Services
worldwide for Quintiles in the USA and in the same year as President: Global
Product Development Services(PDS), and was appointed on the Executive Oppel also chairs the Asia-Pacific Management Board and was appointed Chairman of the Quintiles-Fisher JV, Cenduit, an IRS enterprise in 2007. In
August, 2008 Prof Greeff was appointed professor and head of the
department of Pharmacology, School of Medicine, Faculty of Health Sciences
at the University of Pretoria, retaining his board positions, and relocating
back |